Could a scalp gel save your hair during chemo? early trial begins
NCT ID NCT07033845
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a topical phenylephrine gel applied daily to the scalp for three weeks. Researchers want to see how much of the drug enters the bloodstream and whether it is safe. The study involves 24 healthy women aged 18-55, not cancer patients, so it is a first step toward possibly preventing chemotherapy-induced hair loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Phenylephrine (topical solution applied to scalp)
What this could lead to
If it works, this could point toward a way to reduce hair loss during chemotherapy.
What could go wrong
This is a very early, small study in healthy women, not patients. It only checks safety and absorption, not whether it actually prevents hair loss. Side effects like skin irritation or blood pressure changes are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED ALOPECIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Rome ("G. Marconi")
RECRUITINGRome, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••